Tharimmune, Inc. shares surge 61.54% intraday after announcing positive pharmacokinetic simulation results for TH104.

Tharimmune, Inc. surged 61.54% intraday after announcing positive pharmacokinetic simulation results for its core drug TH104, an oral thin film formulation that shows potential as an effective opioid exposure prevention solution, taking effect within 30 minutes and maintaining protection for approximately 24 hours, potentially outperforming existing treatments like naloxone. The company focuses on developing innovative drugs for unmet medical needs in the immune and inflammatory fields, with TH104 targeting efficient opioid exposure protection in military and emergency scenarios, confirming its core business focus strategy. The FDA previously indicated that a 505b2 new drug application may not require additional clinical trials, streamlining the approval process and enhancing the commercial prospects for TH104.